Aveanna Raises 2025 Revenue Forecast, Launches 2026 Revenue Range While Steering Clear of Net Income Guidance

Ticker: AVAH • EPS and EPS consensus discussions are conspicuously absent from the guidance deck, as the company emphasizes revenue forecasts over per-share metrics in this update.

What Aveanna disclosed

Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH) issued an updated full-year 2025 revenue outlook and unveiled an initial full-year 2026 revenue range, while explicitly declining to provide net income (and thus EPS) guidance for 2026. The company frames the move as part of its ongoing effort to refresh expectations as it navigates a complex, high-cost care environment for medically intricate patients.

Key takeaways from the release include a higher 2025 revenue forecast, a defined 2025 bottom-line and EBITDA targets, and a clear decision not to publish net income guidance for 2026 because of volatility in inputs—most notably fair value adjustments tied to interest rate hedges such as swaps and caps.

Updated Full Year 2025 Guidance (year ending January 3, 2026)

Revenue of approximately $2.425 billion to $2.445 billion — up from a prior outlook of greater than $2.375 billion.
Net income of approximately $181 million to $220 million.
Adjusted EBITDA of approximately $318 million to $322 million.
Normalized Adjusted EBITDA of approximately $298 million to $302 million.

Initial Full Year 2026 Guidance (year ending January 2, 2027)

The company provides a revenue forecast for 2026, calling for revenues between $2.54 billion and $2.56 billion. However, Aveanna notes it will not issue guidance on net income for that year due to volatility in inputs that are not easily forecast, including future fair value adjustments associated with its hedging arrangements.

In other words, the EPS line remains undefined for 2026, and the market will have to infer profitability from the revenue trajectory and the company’s EBITDA discipline rather than a stated per-share target.

What this implies for Aveanna and the home-care sector

Two threads run through Aveanna’s update. First, a modest acceleration in revenue is on the horizon for 2026, implied by the roughly $2.54–$2.56 billion guidance range, which sits above the 2025 midpoints. Second, and more influential for risk assessment, is the decision to withhold net income and EPS guidance because hedging and other hedging-related inputs introduce volatility into earnings reporting. The message is: management prefers to anchor investor expectations on revenue and operating EBITDA, not on volatile fair-value adjustments that swing earnings even before operating performance is considered.

For equity investors, this creates a bifurcated narrative. On the one hand, the higher revenue target for 2026 suggests growth momentum, perhaps from patient volumes, intensity of care, or mix improvements in the home-health portfolio. On the other hand, the lack of net income clarity means EPS consensus is likely to be driven by second-order effects—hedging costs, interest-rate impact, and potential changes in working capital—that can widen or narrow the earnings surprise relative to expectations after the actual results are reported.

Signals for sector peers

Aveanna’s emphasis on revenue and EBITDA, paired with hedging volatility, could set a template for other diversified home-health players facing similar hedging complexities. If investors reward revenue discipline and EBITDA resilience even when GAAP net income remains murky due to hedging inputs, peers with clear mid-term revenue visibility and stable operating margins could see multiple expansion even without clean EPS guidance. The press release also underscores a cautious stance on earnings transparency in environments where fair value adjustments loom large—an issue that could become more prominent for operators with substantial hedging activity or variable reimbursement dynamics.

Bottom line

Aveanna is signaling progress on its 2025 revenue trajectory while deferring clarity on EPS and net income for 2026 because of hedging-driven volatility. The 2025 revenue update is constructive, and the 2026 revenue range hints at continued demand for Aveanna’s home-care platform—the kind of demand shift that can outlast short-term macro swings. For investors and sector peers, the takeaway is less about a single number and more about how the company manages risk and communicates earnings power when hedges complicate the path to per-share profitability.